



(51) International Patent Classification:

A61K 31/404 (2006.01) **A61P 31/00** (2006.01)
A61K 31/4045 (2006.01) **A61P 25/00** (2006.01)
A61K 31/405 (2006.01) **A61P 35/00** (2006.01)
A61K 31/407 (2006.01) **A61P 37/00** (2006.01)
A61K 31/4184 (2006.01) **A61P 43/00** (2006.01)
A61K 31/4188 (2006.01) **A61K 31/4355** (2006.01)
A61K 31/423 (2006.01) **A61K 31/437** (2006.01)
A61K 31/424 (2006.01)

(21) International Application Number:

PCT/EP2015/055823

(22) International Filing Date:

19 March 2015 (19.03.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1406154.3 4 April 2014 (04.04.2014) GB
 1502156.1 10 February 2015 (10.02.2015) GB

(71) **Applicant:** IOMET PHARMA LTD [GB/GB]; Nine Bioquarter, Little France Road, Edinburgh EH16 4UX (GB).

(72) **Inventors:** COWLEY, Philip; c/o IOmet Pharma Ltd, Nine Bioquarter, Little France Road, Edinburgh EH16 4UX (GB). WISE, Alan; c/o IOmet Pharma Ltd, Nine

Bioquarter, Little France Road, Edinburgh EH16 4UX (GB).

(74) **Agent:** HILL, Christopher, Michael; Page White & Far-
rer, Bedford House, John Street, London Greater London
WC1N 2BF (GB).


(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: INDOLE DERIVATIVES FOR USE IN MEDICINE

(I)



(57) **Abstract:** Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X¹, X², X³, X⁴, and X⁵ may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R¹, R², R³, R⁴, R⁵, and R⁷ may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X¹, X², X³, X⁴, and X⁵ are maintained; one or two R⁶ groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R⁶ groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R⁶ is an organic group comprising an atom double-bonded to an oxygen atom (preferably a carbonyl group or a sulfonyl group) at an α -, β -, or γ -position to the carbon atom to which the R⁶ is attached and in which the atom double-bonded to an oxygen atom is also bonded to a hetero-atom.



Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))